InMed Pharmaceuticals Inc.

NasdaqCM:INM Stok Raporu

Piyasa değeri: US$3.5m

InMed Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

InMed Pharmaceuticals' CEO is Eric Adams, appointed in Jun 2016, has a tenure of 8.42 years. total yearly compensation is $415.40K, comprised of 70.8% salary and 29.2% bonuses, including company stock and options. directly owns 0.33% of the company’s shares, worth $11.45K. The average tenure of the management team and the board of directors is 4 years and 2.5 years respectively.

Anahtar bilgiler

Eric Adams

İcra Kurulu Başkanı

US$415.4k

Toplam tazminat

CEO maaş yüzdesi70.8%
CEO görev süresi8.4yrs
CEO sahipliği0.3%
Yönetim ortalama görev süresi4yrs
Yönetim Kurulu ortalama görev süresi2.5yrs

Son yönetim güncellemeleri

Recent updates

InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M

Sep 26

InMed Pharma announces $6M private placement

Sep 09

InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens

Jul 25

InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement

Jul 13

InMed To Acquire Rare Cannabinoid Manufacturer BayMedica

Jul 02

InMed's INM-755 CBN cream did not introduce any delay in normal wound healing

Jan 08

CEO Tazminat Analizi

Eric Adams'un ücretlendirmesi InMed Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024US$415kUS$294k

-US$8m

Mar 31 2024n/an/a

-US$6m

Dec 31 2023n/an/a

-US$6m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023US$368kUS$278k

-US$8m

Mar 31 2023n/an/a

-US$15m

Dec 31 2022n/an/a

-US$17m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022US$468kUS$363k

-US$19m

Mar 31 2022n/an/a

-US$14m

Dec 31 2021n/an/a

-US$14m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021US$735kUS$328k

-US$10m

Mar 31 2021n/an/a

-US$9m

Dec 31 2020n/an/a

-US$7m

Sep 30 2020n/an/a

-US$8m

Jun 30 2020US$424kUS$287k

-US$9m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019n/an/a

-US$11m

Sep 30 2019n/an/a

-US$10m

Jun 30 2019US$1mUS$287k

-US$10m

Mar 31 2019n/an/a

-US$9m

Dec 31 2018n/an/a

-US$8m

Sep 30 2018n/an/a

-US$7m

Jun 30 2018US$2mUS$240k

-US$6m

Tazminat ve Piyasa: Eric's total compensation ($USD415.40K) is below average for companies of similar size in the US market ($USD655.65K).

Tazminat ve Kazançlar: Eric's compensation has increased whilst the company is unprofitable.


CEO

Eric Adams (60 yo)

8.4yrs

Görev süresi

US$415,400

Tazminat

Mr. Eric A. Adams, B.S. Chem., MIBS., has been the Chief Executive Officer and President at InMed Pharmaceuticals Inc. since June 16, 2016. Mr. Adams served as a Strategic Advisor of Augurex Life Sciences...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Eric Adams
President8.4yrsUS$415.40k0.33%
$ 11.5k
N. Jagpal
CFO & Corporate Secretaryless than a yearUS$274.85k0%
$ 0
Michael Woudenberg
Chief Operating Officer2.3yrsUS$349.20k0.00016%
$ 5.6
Alexandra Mancini
Senior Vice President of Clinical & Regulatory Affairs8.1yrsUS$313.60k0%
$ 0
Eric Hsu
Senior Vice President of Preclinical Research & Development6.7yrsUS$322.50k0.00038%
$ 13.2
Sazzad Hossain
Co-Founderno dataUS$142.43kVeri yok
Sarah Li
VP of Accounting & Controller4.8yrsVeri yokVeri yok
Colin Clancy
Senior Director of Investor Relationsno dataVeri yokVeri yok
Jerry Griffin
Vice President of Sales & Marketing2.8yrsVeri yokVeri yok
Shane Johnson
Senior VP & GM of BayMedica3.1yrsVeri yokVeri yok
Ado Muhammad
Senior Consultant of Medical Affairsno dataVeri yokVeri yok

4.0yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: INM's management team is considered experienced (4 years average tenure).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Eric Adams
President8.4yrsUS$415.40k0.33%
$ 11.5k
Andrew Hull
Independent Chair of the Board8.2yrsUS$77.50k0.29%
$ 10.0k
Bryan Baldasare
Independent Director2.5yrsUS$52.50k0%
$ 0
Barry Greenberg
Member of the Scientific Advisory Boardless than a yearVeri yokVeri yok
Janet Grove
Independent Director2.8yrsUS$52.50k0%
$ 0
Nicole Lemerond
Independent Director2.3yrsUS$52.50k0%
$ 0
David Morgan
Member of Scientific Advisory Boardless than a yearVeri yokVeri yok

2.5yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: INM's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.